Director Nancy Lurker buys 3.2K shares of EYPT at $7.88; stock -74.0% from 52-week high; 2 other insiders also bought in past 14 days
Nancy Lurker, a director at EyePoint Pharmaceuticals, purchased 3,173 shares for $25,003.24 on 2024-08-16, increasing her holdings to 97,635 shares. The purchase occurs as the stock trades at $7.72, representing -74.0% from its 52-week high of $29.71, and follows a steep -32.7% decline over the past 90 days. Notably, a cluster of three insiders—including Lurker—have purchased shares within the past 14 days. The company is unprofitable (net income of $-30.8M in its most recent full fiscal year) with quarterly revenue of $9.5M, though it posted annual revenue growth of +11.1%. The convergent buying pattern across multiple insiders during a period of significant price weakness warrants tracking of insider conviction relative to fundamental deterioration and valuation dynamics.